Apollomics, Inc. (NASDAQ:APLM) Sees Significant Drop in Short Interest

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 523,200 shares, a decrease of 6.7% from the August 31st total of 561,000 shares. Approximately 0.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 3,940,000 shares, the days-to-cover ratio is presently 0.1 days.

Apollomics Stock Performance

Shares of Apollomics stock remained flat at $0.13 on Friday. The stock had a trading volume of 439,530 shares, compared to its average volume of 1,578,763. The firm’s 50-day simple moving average is $0.15 and its 200-day simple moving average is $0.30. Apollomics has a 12-month low of $0.11 and a 12-month high of $3.99.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Powell Investment Advisors LLC purchased a new position in Apollomics, Inc. (NASDAQ:APLM) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 130,297 shares of the company’s stock, valued at approximately $98,000. Powell Investment Advisors LLC owned about 0.15% of Apollomics at the end of the most recent quarter. 19.13% of the stock is currently owned by institutional investors.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.